Bibliografia

Bibliografia

  1. Engelhardt PF, Morakis N, Daha LK, et al. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. International urogynecology journal. 2011;22(4):401-5.
  2. Fiander N. Painful bladder syndrome and interstitial cystitis: treatment options. British journal of nursing. 2013;22(9):S26, S8-33
  3. COB Foundation. Cystitis Handbook: The Cystitis & Overactive Bladder Foundation 2012.
  4. Jane M. Meijlink R, editor. Interstitial Cystitis/Bladder Pain Syndrome: Diagnosis & Treatment. IPBF Publication. 2014.
  5. Thompson A, Adamson A, Bahl A, et al. Guidelines for the diagnosis, prevention and management of chemical- and radiation-induced cystitis Journal of Clinical Urology. 2013.
  6. Cicione A, Cantiello F, Ucciero G, et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2014;8(9-10):E721-7.
  7. Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Therapeutic advances in urology. 2011;3(5):223-32.
  8. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. European urology. 2008;53(1):60-7.
  9. The Cystitis and Overactive Bladder (COB) Foundation. COB Foundation Survey. 2009.
  10. Baier Leach J, Schmidt CE. Hyaluronan. Encyclopedia of Biomaterials and Biomedical Engineering2008. p. 1421-31.
  11. Reitinger S, Lepperdinger G. Hyaluronan, a ready choice to fuel regeneration: a mini-review. Gerontology. 2013;59(1):71-6.
  12. Arance I, Ramon de Fata F, et al. [Available evidence about efficacy of different restoring agents of glycosaminoglycans for intravesical use in interstitial cystitis]. Actas urologicas espanolas. 2013;37(2):92-9.
  13. Riedl C, Engelhardt P, Schwarz B. Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines. Clinical drug investigation. 2013;33(10):737-42.
  14. Constantinides C, Manousakas T, Nikolopoulos P, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU international. 2004;93(9):1262-6.
  15. Vedanayagam M, Brewin J, Briggs K, Salahia MG, Hammadeh MY. The role of hyaluronic acid in the management of uncomplicated recurrent female urinary tract infections: literature review and practical experience Journal of Clinical Urology. 2013.
  16. Samper Ots PM, Lopez Carrizosa C, Rodriguez A, de Dios Saez J, Delgado JM, Martin de Miguel M, et al. Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival: a five-year follow-up study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2009;11(12):828-34.
  17. Shao Y, Lu GL, Shen ZJ. Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis. BJU international. 2012;109(5):691-4.
  18. Lv YS, Zhou HL, Mao HP, Gao R, Wang YD, Xue XY. Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. International urogynecology journal. 2012;23(12):1715-20.
  19. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis research & therapy. 2003;5(2):54-67.
  20. Jackson DG. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunological reviews. 2009;230(1):216-31.
  21. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. The Journal of urology. 1996;156(1):45-8.
  22. Necas J, Bartosikova L, Brauner P, KolarJ. Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina. 2008;53(8):397–411.
  23. Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfluger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. International urogynecology journal and pelvic floor dysfunction. 2008;19(5):717-21.
  24. Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scandinavian journal of urology and nephrology. 2005;39(2):143-7.
  25. Sánchez Macías J, Uría González-Tova J, Areal Calama J, et al. [Bladder instillations with hyaluronic acid in the treatment of interstitial cystitis. our experience.] 2005. Available from: http://www.aeu.es/aeu_webs/librosabstracts/ssebastian/abstract.asp?ID=C-90.
  26. Finazzi Agro E, Bove P, Perugia C, et al., editors. Could hyaluronic acid reduce Bacillus Calmette Guérin (BCG) local side effects? A preliminary report. 37th Annual Congress of the Italian Urodynamic Society 2013.
  27. Martinez-Rodriguez R, Areal Calama J, Buisan Rueda O, et al. [Practical treatment approach of radiation induced cystitis]. Actas urologicas espanolas. 2010;34(7):603-9.
  28. Sommariva ML, Sandri SD, Ceriani V. Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis. Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2010;62(2):145-50.
  29. Raport nadzoru podystrybucyjnego.
  30. Ulotka Cystistat dla pacjentów.